REG - Deepverge PLC - Board Appointment

DeepvergeAnnouncement

07/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230207:nRSG0768Pa&default-theme=true

RNS Number : 0768P  Deepverge PLC  07 February 2023

 

7 February 2023

 

DeepVerge PLC

 

("DeepVerge" or "the Company" or "the Group")

 

Board appointment

 

 

DeepVerge (AIM: DVRG), the environmental and life science group of companies
that develops and applies AI and IoT technology to analytical instruments for
the analysis and identification of bacteria, virus and toxins, is pleased to
announce the immediate appointment of Andrew Waters FCA as Chief Financial
Officer (CFO) and as a Director of the Company.

Andrew brings significant experience as a CFO of both public and private
companies in the healthcare and life sciences field, including most recently
at AIM quoted Venture Life Group plc.  Andrew has a Physics degree from
Imperial College and qualified as a Chartered Accountant with
PriceWaterhouseCoopers.

As part of the process of strengthening the Board, a further independent
Non-Executive Director will be appointed as soon as practicable.

Dr Nigel Burton, interim CEO DeepVerge plc, commented:

I'm pleased to welcome Andrew to the Board. In October 2022 we committed to
strengthening the Board, including recruiting a new Group CFO, and are pleased
to have been able to make this appointment in just over three months. As we
seek to grow the Company through a combination of organic growth, joint
ventures and collaborations, Andrew is a welcome addition to the Board with
his relevant international financial and commercial experience.

 

Additional Disclosures Required under the AIM Rules for Companies

In accordance with Schedule 2(g) of the AIM Rules for Companies, Mark Andrew
Waters (aged 56) is, or has been within the previous five years, a director or
partner of the following companies or partnerships:

 

 Current directorships/partnerships  Past directorships/partnerships

 ACP1 Limited                        Venture Life Group plc
 Green Elements Capital Limited      Infirst Healthcare Limited
                                     Infirst Healthcare Inc.
                                     Lubatti Limited
                                     Periproducts Limited
                                     Respicopea Holdings Limited
                                     Respicopea Limited
                                     Immunicopea Limited
                                     Venture Life Limited
                                     Pharmasource BV
                                     MD Manufacturing BV
                                     Nelie BV

 

Andrew Waters does not hold any ordinary shares in the Company.

 

Save as set out above, there is no further information to be disclosed in
respect of Andrew Waters under Schedule 2(g) of the AIM Rules.

 

 DeepVerge plc                                   Nigel Burton, Interim CEO  +44 (0) 7785 234447
 SPARK Advisory Partners Limited                 Neil Baldwin               +44 (0) 113 370 8974

 (Nominated Adviser)
 Turner Pope Investments (TPI) Limited (Broker)  Andy Thacker/James Pope    +44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER
THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF
ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that
develops and applies AI and IoT technology to analytical instruments for the
analysis and identification of bacteria, virus and toxins; Utilising
artificial intelligent data analytics to scientifically prove the impact of
skincare product claims on skin.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOATFMRTMTMMBTJ